TSHA_OUT_1 [2025-04-24 06:13:40 -0400] 5761 Bytes | 1623 tokens | Cum: 1623 tkns (20.29% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Taysha Gene Therapies (TSHA) which is at $1.43 up from $1.24. So, I pulled together a bunch of data for you to look over real fast. It's still early, 6:13 AM on Thu Apr 24, 2025. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Taysha Gene Therapies (TSHA)
IPO: 2020-09-24 (4 Years Ago)
Market Cap: $225,481,295
Shares Outstanding: 205,000,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Here’s a list of headlines for Taysha Gene Therapies:

Apr-21-25 10:00AM - Pz-Cel Has Massive Potential For RDEB Patients
Apr-15-25 04:04PM - Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity
Apr-04-25 08:00AM - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr-01-25 11:50AM - Biotech stocks slide as Marks resignation seen being negative for sector
Mar-19-25 04:31PM - Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts?
Mar-07-25 08:00AM - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb-27-25 01:04AM - Q4 2024 Taysha Gene Therapies Inc Earnings Call
Feb-26-25 09:15AM - Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates
Feb-26-25 09:15AM 08:00AM - Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
Feb-25-25 10:57AM - Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings
Feb-19-25 08:00AM - Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
Feb-07-25 08:00AM - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan-03-25 08:00AM - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec-06-24 08:00AM - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov-14-24 12:51PM - Q3 2024 Taysha Gene Therapies Inc Earnings Call
Nov-14-24 12:51PM 02:16AM - Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ...
Nov-13-24 05:15PM - Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates
Nov-13-24 05:15PM 04:01PM - Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov-06-24 08:00AM - Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
Nov-01-24 04:30PM - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Oct-22-24 08:00AM - Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Oct-16-24 03:42PM - Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds?

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-07T13:00:00Z - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
B2 - 2025-02-07T13:00:00Z - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
B3 - 2024-12-06T13:00:00Z - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
B4 - 2024-10-22T12:00:00Z - Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
B5 - 2024-09-06T12:00:00Z - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
B6 - 2024-06-26T13:14:00Z - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Taysha Gene Therapies (TSHA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

TSHA_OUT_3 [2025-04-24 06:13:41 -0400] 957 Bytes | 306 tokens | Cum: 1931 tkns (24.14% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-23T11:22:03Z - Avoro Capital Advisors LLC Buys 1,349,999 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)...
A2 - 2025-04-23T10:54:19Z - B Group Inc. Buys Shares of 965,556 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)...
A3 - 2025-04-21T07:06:38Z - Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co....
A4 - 2025-04-20T07:03:28Z - Vanguard Group Inc. Raises Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)...
A5 - 2025-04-14T07:31:43Z - Norges Bank Takes $2.53 Million Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TSHA_OUT_5 [2025-04-24 06:13:42 -0400] 1181 Bytes | 344 tokens | Cum: 2277 tkns (28.46% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Avoro Capital Advisors LLC Buys 1,349,999 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)**Date: 2025-04-23Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/avoro-capital-advisors-llc-buys-1349999-shares-of-taysha-gene-therapies-inc-nasdaqtsha-2025-04-21/Avoro Capital Advisors LLC increased its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,999,999 shares of the company's stock after acquiring an additional 1,349,999 shares during the quarter. Taysha Gene Therapies comprises about 0.5% of Avoro Capital Advisors LLC's portfolio, making the stock its 28th largest holding. Avoro Capital Advisors LLC owned approximately 9.76% of Taysha Gene Therapies worth $34,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_7 [2025-04-24 06:13:45 -0400] 1181 Bytes | 299 tokens | Cum: 2578 tkns (32.23% of 8k)
==========================================================================

Showing A1 (chunk 2 of 7): 600,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the stock. State Street Corp boosted its holdings in shares of Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company's stock valued at $6,973,000 after purchasing an additional 150,647 shares during the last quarter. Barclays PLC raised its stake in Taysha Gene Therapies by 356.0% during the third quarter. Barclays PLC now owns 247,280 shares of the company's stock valued at $513,000 after purchasing an additional 193,046 shares in the last quarter. Geode Capital Management LLC lifted its position in Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company's stock valued at $7,163,000 after purchasing an additional 682,273 shares dur

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_9 [2025-04-24 06:13:46 -0400] 1181 Bytes | 314 tokens | Cum: 2894 tkns (36.18% of 8k)
==========================================================================

Showing A1 (chunk 3 of 7): ing the last quarter. Franklin Resources Inc. purchased a new position in shares of Taysha Gene Therapies in the 3rd quarter worth $201,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Taysha Gene Therapies by 1.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company's stock worth $6,033,000 after buying an additional 37,844 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TSHA has been the subject of several recent research reports. Chardan Capital reiterated a "buy" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Eight analys

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_11 [2025-04-24 06:13:47 -0400] 1181 Bytes | 336 tokens | Cum: 3232 tkns (40.40% of 8k)
==========================================================================

Showing A1 (chunk 4 of 7): ts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $6.63.

TSHA opened at $1.24 on Monday. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The business's fifty day simple moving average is $1.54 and its 200-day simple moving average is $1.81. The company has a market capitalization of $254.27 million, a price-to-earnings ratio of 1.97 and a beta of 0.96. Taysha Gene Therapies, Inc. has a 12-month low of $1.05 and a 12-month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negativ

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_13 [2025-04-24 06:13:47 -0400] 1181 Bytes | 304 tokens | Cum: 3538 tkns (44.22% of 8k)
==========================================================================

Showing A1 (chunk 5 of 7): e return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. On average, equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies (

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatmen

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_15 [2025-04-24 06:13:48 -0400] 1181 Bytes | 267 tokens | Cum: 3807 tkns (47.59% of 8k)
==========================================================================

Showing A1 (chunk 6 of 7): t of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Taysha Gene Therapies Right Now?

Before you consider Taysha Gene Therapies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_17 [2025-04-24 06:13:49 -0400] 477 Bytes | 126 tokens | Cum: 3935 tkns (49.19% of 8k)
==========================================================================

Showing A1 (chunk 7 of 7): catches on... and Taysha Gene Therapies wasn't on the list.

While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_19 [2025-04-24 06:13:50 -0400] 1088 Bytes | 298 tokens | Cum: 4237 tkns (52.96% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S2 - 2025-02-26 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our CONS financial statements and related notes. ...

S3 - 2025-02-26 8-K Item2.02 Results of Oper and Fin Cond.

On February 26, 2025, Taysha Gene Therapies, Inc. (the Company ) reported financial results for the year ended December 31, 2024, and recent business highlights. A copy of this press release is furnished as Exhibit 99.1 to...

S4 - 2024-11-13 10-Q PART IFINANCI AL INFO

Item 1. Financi al Stmnts.

Taysha Gene Therapies, Inc.

Condensed Consolida ted Balance Sheets

(in thousands, except share and per share data)

(Unaudited)

September 30, 2024

December 31, 2023

ASSETS

Curr assets:

Cash and cas...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TSHA_OUT_21 [2025-04-24 06:13:51 -0400] 1181 Bytes | 244 tokens | Cum: 4483 tkns (56.04% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes.

Overview

We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. Our management team has prove

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_23 [2025-04-24 06:13:51 -0400] 1181 Bytes | 272 tokens | Cum: 4757 tkns (59.46% of 8k)
==========================================================================

Showing S2 (chunk 2 of 6): n experience in gene therapy development and commercialization. We leverage this experience, our manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.

We currently are conducting two Phase 1/2 clinical trials for TSHA-102: an adolescent/adult study in the United States and Canada and a pediatric study in the United States. In addition, we received approval to expand the pediatric study into the United Kingdom in 2024 following clearance of the CTA by the U.K. MHRA and received approval to expand the pediatric study into Canada in 2024 following clearance of the CTA by Health Canada.

In early 2025, we announced the completion of dosing of the 10 patients in Part A, the dose escalation portion of both REVEAL Phase 1/2 trials, that is expected to serve as primary dataset to support advancement towar

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_25 [2025-04-24 06:13:52 -0400] 1181 Bytes | 299 tokens | Cum: 5058 tkns (63.22% of 8k)
==========================================================================

Showing S2 (chunk 3 of 6): d the Part B registrational trial. Cohort one (low dose cohort of 5.7x10 14 total vg) consists of four patients and cohort two (high dose cohort of 1x10 15 total vg) consists of six patients across both REVEAL trials. In early 2025, we announced TSHA-102 was generally well-tolerated with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) related to TSHA-102 in the 10 pediatric, adolescent and adult patients dosed across the two REVEAL Phase 1/2 trials as of the February 17, 2025, data cutoff.

We have received orphan drug designation and rare pediatric disease designation from the United States Food and Drug Administration, or FDA, and orphan drug designation from the European Commission for TSHA-102 for the treatment of Rett syndrome. We also received Fast Track Designation from the FDA for TSHA-102 for the treatment of Rett syndrome. We also received CTA clearance fro

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_27 [2025-04-24 06:13:53 -0400] 1181 Bytes | 267 tokens | Cum: 5327 tkns (66.59% of 8k)
==========================================================================

Showing S2 (chunk 4 of 6): m the United Kingdoms Medicines and Healthcare Products Regulatory Agency, or U.K. MHRA, in early 2024 for pediatric patients with Rett syndrome. In February 2024, we received Innovative Licensing and Access Pathway, or ILAP, designation for TSHA-102 from the U.K. MHRA. The ILAP aims to facilitate patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with U.K. regulatory authorities and other stakeholders. In April 2024, the FDA granted Regenerative Medicine Advanced Therapy, or RMAT, designation for TSHA-102 in Rett syndrome. Sponsor companies receiving RMAT designation can benefit from increased interactions with the FDA involving senior managers, with the goal of expediting drug development.

We completed a CMC-focused Type D with the FDA in the fourth quarter of 2024. The FDA endorsed our intended Good Manufacturing Practice

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_29 [2025-04-24 06:13:54 -0400] 1181 Bytes | 233 tokens | Cum: 5562 tkns (69.53% of 8k)
==========================================================================

Showing S2 (chunk 5 of 6): , or GMP, commercial manufacturing process, proposed analytical methods, and corresponding qualification and validation plans, including key mechanism of action potency release assays. We also established analytical comparability between the clinical product and the product derived from the final commercial manufacturing process, and received FDA permission to use the GMP product in future clinical studies of TSHA-102.

We have a limited operating history. Since our inception, our operations have focused on organizing and staffing our company, business planning, raising capital and entering into collaboration agreements for conducting preclinical and clinical development activities for our product candidates. Our lead product candidate is still in the clinical stage. We do not have any product candidates approved for sale and have not generated any revenue from product sales. Through De

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_31 [2025-04-24 06:13:55 -0400] 790 Bytes | 201 tokens | Cum: 5765 tkns (72.06% of 8k)
==========================================================================

Showing S2 (chunk 6 of 6): cember 31, 2024, we have funded our operations primarily through: (i) the sale of equity, raising an aggregate of $671.0 million of gross proceeds from our initial public offering, or the IPO, sales of common stock pursuant to our Sales Agreement (as defined below), our October 2022 follow-on offering, our 2023 private placement and our June 2024 Offering (as defined below); (ii) pre-IPO private placements of our convertible preferred stock; (iii) our Term Loan Agreement (as defined below) and subse...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TSHA_OUT_33 [2025-04-24 06:14:01 -0400] 6362 Bytes | 1707 tokens | Cum: 7474 tkns (93.42% of 8k)
==========================================================================

This is our set of metrics for Taysha Gene Therapies.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+------------------------+
| Volume: 3,994,205 | Perf Month: 9.64% | Option/Short: Yes / Yes | Sales Y/Y TTM: -46.07% |
+-------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 2.17M | Perf Quarter: 18.95% | Short Float: 13.11% | ROE: -121.94% |
+-------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 1.86 | Index: RUT | Short Ratio: 9.95 | ROI: -67.04% |
+-------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 64.54 | Market Cap: 373.20M | Short Interest: 21.63M | Sales Surprise: -5.68% |
+-------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 0.17 | Shs Outstand: 204.94M | Beta: 0.80 | EPS Surprise: 13.90% |
+-------------------+-----------------------+-------------------------+------------------------+
| SMA20: 29.68% | Shs Float: 165.06M | Sales Q/Q: -43.90% | P/E: - |
+-------------------+-----------------------+-------------------------+------------------------+
| SMA50: 16.19% | Inst Own: 77.23% | Sales past 5Y: 94.30% | Earnings: Feb 26 BMO |
+-------------------+-----------------------+-------------------------+------------------------+
| SMA200: -5.69% | Insider Own: 19.51% | Employees: 73 | |
+-------------------+-----------------------+-------------------------+------------------------+
| Perf Week: 43.31% | Insider Trans: 0.00% | Debt/Eq: 0.89 | |
+-------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading by Taysha Gene Therapies officers or majority shareholders (if available).

Inside Trans: Taysha Gene Therapies, Inc. (TSHA) by Alam Kamran (CHIEF FINANCIAL OFFICER) on 2025-03-11
- Common Stock: 29843 shares at $1.69 (D) Footnote: Represents shares withheld by the Issuer to satisfy the tax withholding obligations triggered by the vesting and settlement of restricted stock units and does not represent a discretionary transaction by the Reporting Person.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 8333000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -89298000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.82
Average Volume: 2677779.1
30-Day High: 1.93
30-Day Low: 1.13

[Detailed Financials: TTM 2024]
- Total Assets: $160,364,000.00
- Total Liabilities: $88,839,000.00
- Total Equity: $71,525,000.00
- Current Assets: $142,130,000.00
- Current Liabilities: $26,227,000.00

[Income Statement: TTM 2024]
- Revenue: $8,333,000.00
- Net Income: $-89,298,000.00
- Gross Profit: N/A
- Operating Income: $-91,459,000.00
- Earnings Per Share (EPS): -0.36

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-4,904,000.00

[Detailed Financials: FY 2024]
- Total Assets: $160,364,000.00
- Total Liabilities: $88,839,000.00
- Total Equity: $71,525,000.00
- Current Assets: $142,130,000.00
- Current Liabilities: $26,227,000.00

[Income Statement: FY 2024]
- Revenue: $8,333,000.00
- Net Income: $-89,298,000.00
- Gross Profit: N/A
- Operating Income: $-91,459,000.00
- Earnings Per Share (EPS): -0.36

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-4,904,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Taysha Gene Therapies (TSHA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Taysha Gene Therapies.

2) MARKET_SCORE[]
This conversation was initiated because TSHA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for TSHA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, TSHA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect TSHA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Taysha Gene Therapies.

11) ETHICAL_RATING[]
Rate Taysha Gene Therapies’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Taysha Gene Therapies.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

TSHA_IN_35 [2025-04-24 06:14:02 -0400] 126 Bytes | 29 tokens | Cum: 7710 tkns (96.38% of 8k)
==========================================================================

====================================
[2025-04-24 06:14:02] # Analysis Completed
Elapsed Time: 23.19 seconds